9月11日 - ** 药物开发商Maze Therapeutics MAZE.O股价盘前上涨35%至21.77美元
** 公司称其实验性口服药物MZE782在一项早期试验中显示出强劲的效果
** 这种药物能阻断一种名为SLC6A19的蛋白质，导致尿液中排出的苯丙氨酸和谷氨酰胺量急剧增加
** 公司表示计划于 2026 年开始针对苯丙酮尿症（一种罕见的遗传性疾病）和慢性肾病（一种影响肾功能的长期疾病）的中期研究
** 公司表示，在对112名健康成年人进行的药物测试中，没有发现严重的副作用。
** 截至上一交易日收盘，股价累计上涨 0.4
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.